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To the Editor:
Iohexol is regarded as an accurate ﬁltration marker for measuring
GFR. Recently, Soveri et al1 concluded that plasma clearance of
iohexol could be considered a valid alternative to the gold standard,
urinary clearance of inulin. Because inulin urinary clearance is
cumbersome and costly, iohexol and iothalamate clearance have
become popular in Europe and the United States, respectively. To
advance GFR research, it therefore seems relevant to directly
compare these 2 methods. Seegmiller et al2 recently highlighted
discordance between urinary clearance of iothalamate and iohexol
measured by LC-MS/MS; iohexol clearance wasw15% lower than
iothalamate clearance. However, at least for iohexol, plasma
disappearance is generally used in clinical practice and research.3-5
Here, we concomitantly measured GFR by plasma clearance of
both iohexol and iothalamate in 102 patients. Indications for GFR
measurement were kidney function evaluation in either potential
living kidney donors or patients whose serum creatinine–based
GFR estimation was suspected as inaccurate.6 The protocol had
ethics committee approval (Belgian number: B7072014220701).
All patients signed informed consent. Five mL of iohexol (Omni-
paque 240, 240 mg/mL; GE Healthcare BVBA) and 5 mL of
iothalamate (Conray 30; iothalamate meglumine, 141 mg/mL;
Covidien) were administered simultaneously in the same vein
(antecubital, forearm, or hand vein) and ﬂushed with 10 mL of
normal saline solution. Blood samples were obtained using the
contralateral arm at 120, 180, 240, and 300 minutes after injection
and GFR was calculated as per Brochner-Mortensen.7 Samples
were centrifuged for 10 min at 3,000 g within 2 hours of collection
and stored at280C. Iohexol was measured by 2 methods (HPLC,
as previously described,8 and LC-MS/MS); iothalamate was
measured by LC-MS/MS (analytical methods in Item S1). Our
laboratory participates in interlaboratory quality control performed
by Equalis AB (Uppsala, Sweden) using both methods 4 times a
year. Clearance results were analyzed by Passing-Bablok re-
gressions and concordance correlation coefﬁcient (CCC). For
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Figure 1. Passing-Bablok regressions: comparison of GFR mea
measured by HPLC (high-performance liquid chromatography; left p
confidence intervals) is y 5 0.88x 1 7 (0.82, 0.94; 3, 11). With io
mass spectrometry; right panel), the equation for the regression lin
(0.85, 0.92; 21, 4). The grey line is the identity line.
Am J Kidney Dis. 2016;-(-):---difference between iohexol and iothalamate divided by the mean of
iohexol and iothalamate results. Accuracy within 30% and 15%
were computed as percentage of iothalamate results 630% or
615%, respectively, of the mean of iohexol and iothalamate results.
Clinical characteristics of the study population are given in table
a of Item S1. Mean GFRs measured by iohexol using HPLC and
LC-MS/MS were 776 25 and 71 6 25 mL/min/1.73 m2, respec-
tively, and by iothalamate, 806 29 mL/min/1.73 m2. Figure 1
shows Passing-Bablok regression comparisons; CCC analyses
are in ﬁgures a and b of Item S1. Relative bias between iohexol
and iothalamate (HPLC and LC-MS/MS) results were 22% 6
13% (P5 0.2) and 211% 6 9% (P , 0.001), respectively
(Fig 2). Accuracy within 30% was 98% and 99% (P 5 0.9), and
within 15% was 80% and 74% (P 5 0.4). Item S1 ﬁgures c to e
show agreement analyses between GFR measured by iohexol
using HPLC or LC-MS/MS.
We found acceptable concordance between iohexol and iotha-
lamate plasma clearance compared to the intraindividual variation
of measured GFR ofw10%.9 Using HPLC to measure iohexol, we
detected no signiﬁcant difference between iohexol and iothalamate
clearance, but as in the study by Seegmiller et al,2 using LC-MS/
MS–measured iohexol gave signiﬁcantly lower iohexol versus
iothalamate clearance. Thus, the method for measuring iohexol or
iothalamate can inﬂuence results. Additional studies are necessary
to explain the analytical bias observed in the 2 methods. In the
absence of urinary inulin clearance, we cannot deﬁnitively conclude
which method is best. However, because iothalamate is secreted by
tubules, the 10% lower results observed with LC-MS/MS iohexol
plasma clearance might be closer to the true GFR value.
Plasma clearance slightly overestimates urinary clearance,
whatever the marker used.10 However, we think that plasma
clearance is the best compromise between physiology and feasi-
bility in clinical routine. Plasma clearance is far less cumbersome
(and costly), especially in elderly and young children, for whom
urine collection is very challenging. As demonstrated here, the
easy-to-use plasma method gives comparable results using either
iohexol or iothalamate. The concordance is sufﬁcient to recom-
mend either of these 2 methods in daily practice. Still, depending
on the method used to measure iohexol, a slight bias may be
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sured by iohexol (y-axis) and iothalamate (x-axis). With iohexol
anel), the equation for the regression line (black line; with 95%
hexol measured by LC-MS/MS (liquid chromatography–tandem















































































Figure 2. Bland-Altman analysis: comparison of GFR measured by iohexol and iothalamate (iohexol measured by HPLC [left],
iohexol measured by LC-MS/MS [right]).
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